Remibrutinib (Ruipoduo): Safety, Side Effects, and Usage Guidelines

　　Remibrutinib(brand name Ruipoduo)is a highly selective Bruton's tyrosine kinase(BTK)inhibitor primarily used for chronic spontaneous urticaria.As a new-generation BTK inhibitor,it demonstrates excellent safety and tolerability in allergic diseases.

　　1.Safety Profile and Common Side Effects​

　　Clinical trials indicate good safety and tolerability.Common adverse reactions are mild to moderate,mainly including headache,nausea,diarrhea,and upper respiratory tract infections.Severe adverse events occur at rates similar to placebo,aligning with the side effect spectrum of BTK inhibitors.

　　2.Management of Headache​

　　Headache is one of the most common side effects,typically mild-to-moderate and short-lived.Rest and adequate sleep are recommended;acetaminophen may be used if needed.Seek medical attention if headaches worsen or change in nature.

　　3.Gastrointestinal Reaction Response​

　　Nausea and diarrhea are relatively common.Mild diarrhea can be managed with dietary adjustments;nausea may improve with small,frequent meals and avoiding irritants.Antiemetic or antidiarrheal drugs can be considered for persistent symptoms.

　　4.Infection Prevention​

　　As BTK is involved in immune cell function,infection risk may slightly increase.Maintain personal hygiene,avoid exposure to pathogens,and seek prompt medical care for fever,cough,or urinary frequency.

　　5.Hematological Monitoring​

　　Although impact on the blood system is minimal,regular complete blood count(CBC)tests(monitoring white blood cells,platelets)are advised.Prompt management is required for significant decreases.

　　6.Importance of Long-Term Follow-Up​

　　For long-term chronic disease treatment,regular follow-ups are essential to assess efficacy and safety.Doctors will adjust regimens based on individual needs to optimize outcomes.